Psychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker2, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Harm Reduction Journal, 2019, 16, 43, 1-10 https://doi.org/10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the [...]
Lire la suitePrevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness Receiving Treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, (1), 133-138 DOI: 10.1089/can.2017.0006 Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]
Lire la suiteADDICTIONS & troubles psychiatriques, REPERES Fédération Addiction, mai 2019 Avant-Propos L’association entre les pathologies addictives et psychiatriques est une source majeure de préoccupation et de difficultés pour les professionnels et les équipes des deux champs mais aussi et avant tout pour les personnes concernées et leur entourage, avec une qualité de vie fortement altérée. Ces comorbidités, ces pathologies associées ou duelles, selon les qualifications, sont en effet difficiles à repérer et à prendre en charge, chaque filière de soins, psychiatrique ou addictologique, ayant tendance à concentrer son attention et ses interventions sur la pathologie de son domaine d’expertise. Leur pronostic est péjoratif, l’évolution [...]
Lire la suiteThe Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019 Abstract: Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]
Lire la suite